RxDoctor Payments Data

Flavius Nascimento

Gerontology · Coral Springs, FLNPI 1730625757

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $160,288 of the $225,719 with a category attached, or 71.0%. Fresenius USA Marketing, Inc. accounts for 94.2% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2023 at $95,551 and has fallen 81.6% since, to $17,550 in 2025. Among gerontology clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$225,719in general payments, 2019–2025

Across 400 payments — averaging $564.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Fresenius USA Marketing, Inc.$213K
  • Akebia Therapeutics Inc$12K
  • AstraZeneca$145
  • Vifor Pharma, Inc.$125
  • Travere Therapeutics, Inc.$99
  • Amgen$70
  • plus $219 from 6 others

What the payments were for

  • Consulting fees$12,7506%
  • Speaking & faculty fees$160,28871%
  • Travel & lodging$45,25720%
  • Food & beverage$7,4243%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$225,719 in reported general payments places this provider in the 95th percentile of 714 gerontology providers in Florida.

See all gerontology providers in Florida

Medicare billing

Part B allowed, 2024
$16,959
Medicare patients
47
Services billed
84

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VelphoroSucroferric Oxyhydroxide119$275,452
AuryxiaFerric Citrate25$53,719
EliquisApixaban14$20,638
ProsolParenteral Amino Acid 20% No.131$7,260
Sevelamer Carbonate49$6,806
Calcium Acetate16$2,343
Nifedipine ErNifedipine19$603
Midodrine Hcl15$438
Gabapentin16$242
Hydralazine Hcl16$220
Losartan Potassium30$205
Lidocaine-PrilocaineLidocaine/Prilocaine11$170
Tamsulosin Hcl13$139
Mupirocin14$136
Lisinopril17$136

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Fresenius USA Marketing, Inc.Velphoro$212,687$275,452119 claims
Akebia Therapeutics IncAuryxia$12,373$53,71925 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 714 gerontology providers in Florida.

Other gerontology in Coral Springs

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →